- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-SLAF7/ CS1/ SLAMF7 monoclonal antibody
Anti-SLAF7/ CS1/ SLAMF7 antibody for FACS & in-vivo assay
Go to CS1/SLAMF7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T98052-Ab-1/ GM-Tg-hg-T98052-Ab-2 | Anti-Human CS1/SLAMF7 monoclonal antibody | Human |
| GM-Tg-rg-T98052-Ab-1/ GM-Tg-rg-T98052-Ab-2 | Anti-Rat CS1/SLAMF7 monoclonal antibody | Rat |
| GM-Tg-mg-T98052-Ab-1/ GM-Tg-mg-T98052-Ab-2 | Anti-Mouse CS1/SLAMF7 monoclonal antibody | Mouse |
| GM-Tg-cynog-T98052-Ab-1/ GM-Tg-cynog-T98052-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CS1/SLAMF7 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T98052-Ab-1/ GM-Tg-felg-T98052-Ab-2 | Anti-Feline CS1/SLAMF7 monoclonal antibody | Feline |
| GM-Tg-cang-T98052-Ab-1/ GM-Tg-cang-T98052-Ab-2 | Anti-Canine CS1/SLAMF7 monoclonal antibody | Canine |
| GM-Tg-bovg-T98052-Ab-1/ GM-Tg-bovg-T98052-Ab-2 | Anti-Bovine CS1/SLAMF7 monoclonal antibody | Bovine |
| GM-Tg-equg-T98052-Ab-1/ GM-Tg-equg-T98052-Ab-2 | Anti-Equine CS1/SLAMF7 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T98052-Ab-1/ GM-Tg-hg-T98052-Ab-2; GM-Tg-rg-T98052-Ab-1/ GM-Tg-rg-T98052-Ab-2; GM-Tg-mg-T98052-Ab-1/ GM-Tg-mg-T98052-Ab-2; GM-Tg-cynog-T98052-Ab-1/ GM-Tg-cynog-T98052-Ab-2; GM-Tg-felg-T98052-Ab-1/ GM-Tg-felg-T98052-Ab-2; GM-Tg-cang-T98052-Ab-1/ GM-Tg-cang-T98052-Ab-2; GM-Tg-bovg-T98052-Ab-1/ GM-Tg-bovg-T98052-Ab-2; GM-Tg-equg-T98052-Ab-1/ GM-Tg-equg-T98052-Ab-2 |
| Products Name | Anti-CS1/SLAMF7 monoclonal antibody |
| Format | mab |
| Target Name | CS1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CS1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-INN-746 | Pre-Made Azintuxizumab Vedotin Biosimilar, Whole Mab Adc, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody Drug Conjugate |
| Biosimilar | GMP-Bios-ab-172 | Pre-Made Elotuzumab biosimilar, Whole mAb, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody |
| Biosimilar | GMP-Bios-ab-043 | Pre-Made Azintuxizumab biosimilar, Whole mAb ADC, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody |
| Target Antigen | Products Developing | Multi-species SLAF7/ CS1/ SLAMF7 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLPm001759 | mouse Slamf7 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001759 | mouse Slamf7 Lentivirus particle |
Target information
| Target ID | GM-T98052 |
| Target Name | CS1 |
| Gene ID | 57823,75345,364049,719781,609992,101089574,790164,100058797 |
| Gene Symbol and Synonyms | 19A,19A24,4930560D03Rik,CD319,CRACC,CS1,RGD1560190,SLAMF7 |
| Uniprot Accession | Q9NQ25 |
| Uniprot Entry Name | SLAF7_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index |
| Disease | N/A |
| Gene Ensembl | ENSG00000026751 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: CS1, gene name: SLAMF7, also named as 19A, CD319, CRACC, CS1. Enables identical protein binding activity. Predicted to be involved in adaptive immune response. Predicted to act upstream of or within regulation of natural killer cell activation. Located in endoplasmic reticulum. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
